Durham, NC (Vocus) November 3, 2010
The Society for Translational Oncology (STO) awards the 2010 Bob Pinedo Cancer Care Prize to Dr. Jose Baselga of the Massachusetts General Hospital Cancer Center, Harvard University, at its annual meeting in Boston.
Dr. Baselga was awarded the prize for his exceptional contribution to improved care for cancer patients. In honor of his award, Dr. Baselga delivered the keynote lecture “Building a Vision for the Future in Development of Targeted Therapeutics” at the STO meeting on Monday, November 1. This lecture will be published in STO’s official peer-reviewed journal, The Oncologist.
Dr. Baselga relocated from Barcelona, Spain in the summer of 2010 to become chief of the Division of Hematology/Oncology and associate director of the Mass General Cancer Center. He has made seminal advances in breast cancer research, developing new, targeted cancer-fighting agents. Dr. Baselga was chairman of the Medical Oncology Service and director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron Institute of Oncology, Barcelona, Spain. He was the founder and director of the Vall d’Hebron Institute of Oncology, and a professor of medicine at the Universidad Autonoma de Barcelona. A recipient of many distinguished awards, Dr. Baselga will, on November 18, receive from Queen Sofia of Spain the coveted Echevarne Foundation National Prize in Oncology, one of Spain’s highest honors.
As Dr. Richard M. Goldberg, co-chairman of STO said, “Dr. Baselga’s accomplishments in advancing cancer care through drug development informed by findings from his laboratory on the changes that drive cancers at the molecular level clearly exemplify the ideals that Professor Pinedo has championed as a researcher and caregiver. Jose’s lifetime commitment to advancing cancer care, especially for breast cancer patients, makes him a deserving recipient of this honor.”
The Pinedo Cancer Care Prize, founded in 2006, honors Professor H.M. (Bob) Pinedo, founder of the VU University Medical Center (VUmc) Cancer Center Amsterdam (CCA) and honors the legacy of its namesake, who wedded world-class cancer research with a devotion to his patients and their families. It is this dual legacy that The Pinedo Prize celebrates. The award includes a bronze trophy and $50,000.
Past Prize winners are Dr. Bruce Chabner (Massachusetts General Hospital Cancer Center), Dr. Joseph Bertino (New Jersey Cancer Center), Dr. Bob Löwenberg (Erasmus Medical Center, Rotterdam) and Dr. Richard O’Reilly (Memorial Sloan-Kettering Cancer Center). Founded by the Medical Knowledge Institute (MKI), the Society for Translational Oncology became heir to the Pinedo Prize in 2009.
Nominations for the 2011 Pinedo Prize should be sent to Professor Patrick Johnston, Chairman, Nominating Committee: Pinedo(dot)Prize(at)STO-online(dot)org. Deadline for submitting nominations is May 2, 2011. All nominees will be evaluated by an international nominating committee.
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://theoncologistcommunity.com/society-for-translational-oncology.html
About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its fifteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.
About Massachusetts General Hospital
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. Mass General conducts the largest hospital-based research program in the United States, with an annual research budget of more than $600 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine. For more information visit: http://www.massgeneral.org/